This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2006 Mar;21(3):562-8.

doi: 10.1093/ndt/gfi336. Epub 2005 Dec 16.

Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks

Fritz Diekmann, Josep M Campistol

PMID: 16361278
DOI: 10.1093/ndt/gfi336

Review

Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks

Fritz Diekmann et al. Nephrol Dial Transplant. 2006 Mar.

. 2006 Mar;21(3):562-8.

doi: 10.1093/ndt/gfi336. Epub 2005 Dec 16.

Authors

Fritz Diekmann, Josep M Campistol

PMID: 16361278
DOI: 10.1093/ndt/gfi336

No abstract available

PubMed Disclaimer

Comment on

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L. Bumbea V, et al. Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. doi: 10.1093/ndt/gfh957. Epub 2005 Jun 28. Nephrol Dial Transplant. 2005. PMID: 15985508

Similar articles

Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C. Falger JC, et al. Pediatr Transplant. 2006 Jun;10(4):474-8. doi: 10.1111/j.1399-3046.2006.00503.x. Pediatr Transplant. 2006. PMID: 16712606
Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria.
Saurina A, Campistol JM, Piera C, Diekmann F, Campos B, Campos N, de las Cuevas X, Oppenheimer F. Saurina A, et al. Nephrol Dial Transplant. 2006 Feb;21(2):488-93. doi: 10.1093/ndt/gfi266. Epub 2005 Nov 9. Nephrol Dial Transplant. 2006. PMID: 16280369
Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C. Falger JC, et al. Pediatr Transplant. 2006 Aug;10(5):565-9. doi: 10.1111/j.1399-3046.2006.00515.x. Pediatr Transplant. 2006. PMID: 16856992
[Replacing calcineurin inhibitors with proliferation signal inhibitors after kidney transplantation: indications, results, and disadvantages].
Audard V. Audard V. Nephrol Ther. 2009 Dec;5 Suppl 6:S395-9. doi: 10.1016/S1769-7255(09)73432-7. Nephrol Ther. 2009. PMID: 20129452 Review. French.
mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
Letavernier E, Legendre C. Letavernier E, et al. Transplant Rev (Orlando). 2008 Apr;22(2):125-30. doi: 10.1016/j.trre.2007.12.001. Transplant Rev (Orlando). 2008. PMID: 18631865 Review.

See all similar articles

Cited by

Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant Patients.
Zimmerman KO, Wu H, Greenberg R, Guptill JT, Hill K, Patel UD, Ku L, Gonzalez D, Hornik C, Jiang W, Zheng N, Melloni C, Cohen-Wolkowiez M. Zimmerman KO, et al. Ther Drug Monit. 2016 Oct;38(5):600-6. doi: 10.1097/FTD.0000000000000313. Ther Drug Monit. 2016. PMID: 27259059 Free PMC article.
Conversion to sirolimus of patients with chronic allograft nephropathy--a retrospective analysis of outcome and influencing factors.
Witzke O, Viklicky O, Türk TR, Lutz J, Wilde B, Willenberg I, Vitko S, Heemann U. Witzke O, et al. Langenbecks Arch Surg. 2009 Nov;394(6):1073-8. doi: 10.1007/s00423-008-0435-y. Epub 2008 Nov 20. Langenbecks Arch Surg. 2009. PMID: 19020895
Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.
Yu JH, Kim KW, Kim BM, Chung BH, Cho ML, Choi BS, Park CW, Kim YS, Yang CW. Yu JH, et al. Korean J Intern Med. 2016 May;31(3):552-9. doi: 10.3904/kjim.2014.366. Epub 2016 Mar 11. Korean J Intern Med. 2016. PMID: 26968190 Free PMC article.
The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients.
Kim KW, Chung BH, Kim BM, Cho ML, Yang CW. Kim KW, et al. Immunology. 2015 Jan;144(1):68-78. doi: 10.1111/imm.12351. Immunology. 2015. PMID: 24974886 Free PMC article. Clinical Trial.
Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model.
Sereno J, Romão AM, Parada B, Lopes P, Carvalho E, Teixeira F, Reis F. Sereno J, et al. J Pharmacol Pharmacother. 2012 Apr;3(2):143-8. doi: 10.4103/0976-500X.95513. J Pharmacol Pharmacother. 2012. PMID: 22629089 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information